Why We Stopped Trying to Make the Quarterly Report Faster

Medical affairs has a cadence problem. Here is how we set out to close the gap between evidence and action.

Spend enough time with medical affairs leaders and you hear a version of the same thing. The quarterly insights report arrives, the team gathers to read it, and somewhere in the room is the quiet understanding that the picture it describes is already weeks old. The work that went into it was real. The science it summarizes has simply moved on. Up to 5,000 biomedical papers publish every day, and no document assembled on a quarterly rhythm can keep pace with that. The report is not wrong. It is late.

For a long time the industry treated this as a data access problem, and so the answer was always more: more sources, more coverage, more volume. That was the wrong diagnosis. Medical affairs teams have access to plenty of evidence, but they are short on timely meaning. And life sciences organizations simply cannot commercialize a precision therapy on an evidence picture that is a quarter behind the conversation.

So we stopped asking how to make the quarterly report faster and started asking a different question: what would medical affairs use if the instrument itself were continuous?

Redefining Scientific Impact: What “Resonance” Actually Means

The answer we arrived at is the Therapy Resonance Profile (TRP).

To understand its value, you have to look at how we define the core metric: Resonance.

In Medical Affairs, tracking sentiment or alignment independently creates a false sense of security.

Sentiment alone is insufficient: A Key Opinion Leader (KOL) can admire your clinical data while still drifting away from the strategic position your evidence supports.

Alignment alone is a lagging indicator: A stakeholder can be strategically aligned on paper while their active engagement and enthusiasm for your science quietly cools.

Resonance is the real-time intersection of the two. It continuously tracks whether the stakeholders who matter are actively moving toward your strategic position, and whether the momentum surrounding your science is warming or cooling.

What makes this metric an instrument for action—rather than a decorative dashboard—is absolute traceability. A score that cannot explain why it moved is just a digital version of the subjective survey it was meant to replace. The Therapy Resonance Profile is built directly on underlying evidence. That means it answers the immediate question that follows every chart an executive looks at: Why?

You see exactly where your narrative stands, you understand the clinical signals driving the shift, and you watch it evolve in real time. This means medical science liaison (MSL) deployment and medical strategy can go where they will matter next week, rather than where they mattered last quarter.

Why a framework, not a feature

Underneath the read sits the Strategic Alignment Framework, and it is deliberately a framework rather than a single feature, because the problem it solves is structural.

The shift it makes is from pull to push. For years the bet across the category of AI and data intelligence was to give people an excellent way to ask the system questions. That is necessary, and it still matters. But it puts the entire burden on the human to know what to ask and to remember to ask it at the moment it counts. The next bet is that the system surfaces the answer before you ask, because it already holds your strategic imperatives and it is watching the evidence against them. When a gap opens between where your science is and where your strategy needs it to be, the framework pushes that forward into the workflow rather than waiting to be queried.

The discipline here is precision. Push only earns trust if it is sparing. Nobody in medical affairs wants another alert stream. So the framework is tuned to surface the gap that could stall clinical adoption of a therapy, not to narrate every fluctuation.

Here is what that sparing, push-based framework looks like in practice:

Stakeholder Alignment scores where each stakeholder stands relative to your objectives and tracks that posture over time. The job it does is the one MSL leads describe most often: tell me where the field team should spend their time, and tell me why, so the plan reflects who is actually moving the narrative rather than who we happened to see last.

Automated Medical Insights Reports replace the analyst-weeks that went into the quarterly deck, and the real innovation is not just that they are produced automatically. It is in highlighting the delta. People do not need the entire picture re-rendered every month. They need to know what changed and whether it matters. So the report leads with the change against the previous monthly snapshot, which turns a backward-looking summary into a leading indicator.

Key intelligence questions often die in static slides that no one updates. To fix this, we built the Key Intelligence Topics and Questions (KIT/KIQ) Matrix. As the first of those automated reports, the Matrix keeps these topics living: providing one view of the questions that matter, what has shifted since the last report, and links to the current and prior snapshots, for objectives as specific as how a competitor drug is being perceived.

Built, not bolted

I want to be precise about one thing, because the category invites the opposite. None of this is conceptual, and none of it is stapled onto a legacy reporting tool.

The read emerges from the same underlying evidence spine that already powers our platform. Whether the signal comes from a published journal or a conversation captured at a congress, it flows into one continuous read. It is built natively for a continuous world, not bolted onto an older one.

Record, intelligence, action

The simplest way to describe where this sits is as the next step in an arc.

A system of record put the evidence in one place and made it traceable. A system of intelligence went further and told you what the evidence means, where you stand and why. The frontier now is a system of action, where the platform shows a team where to focus and helps them act on it. The Therapy Resonance Profile and the Strategic Alignment Framework are the start of this next step, partly through push intelligence and the engagement prioritization shipping today, and partly through a road we are honest about still building.

What I keep coming back to is that none of this originated in a strategy session. It came from the same conversations I opened with, where the gap between what the science said and what the team could act on was measured in quarters. The roadmap is set by what medical affairs teams keep asking for, and the measure of whether we got this right is plain: can a team act a quarter earlier than they could before. When they can, the rest of the mission follows, which is the right science reaching the right clinicians, and the right patients, sooner.